CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
工程化 T 细胞免疫治疗在自身免疫及其他非肿瘤疾病中的进展
英文原题：Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases.
查看英文原题
Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
使用表达嵌合抗原受体的工程化T细胞进行的过继性免疫治疗在治疗血液系统恶性肿瘤患者中已显示出显著成功。然而，要实现工程化T细胞在其他疾病中更广泛的治疗应用，还需要在临床研究中进一步探索。在这篇综述中，我们重点介绍了T细胞工程在非肿瘤领域的最新进展，包括自身免疫性和炎症性疾病、感染、纤维化、血友病和衰老。嵌合抗原受体免疫治疗在非肿瘤领域已显示出良好结果，但在提高其安全性和有效性以及将其应用扩展到非肿瘤疾病治疗方面仍存在许多挑战。
展开英文摘要原文
Adoptive immunotherapy using engineered T cells expressing chimeric antigen receptors has shown remarkable success in treating patients with hematological malignancies.
However, realizing broader therapeutic applications of engineered T cells in other diseases requires further exploration in clinical investigations. In this review, we highlight recent advances in the engineering of T cells in non-oncology areas, including autoimmune and inflammatory diseases, infections, fibrosis, hemophilia, and aging.
Chimeric antigen receptor immunotherapy has shown good outcomes in non-oncology areas, but many challenges remain in improving its safety and efficacy and and expanding its application to the treatment of non-oncological diseases.
论文信息
- 作者
- Huang Q、Zhu X、Zhang Y
- 第一作者单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.China
- 通讯作者单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China. yczhang@tjh.tjmu.edu.cn.China
- 文献类型
- 综述
- 期刊
- Biomarker research2025 Feb 4
- 原文标识
- PubMed 39901288 · DOI 10.1186/s40364-025-00736-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →